20 citations
,
May 2015 in “Regenerative Medicine” This commentary explores the marketing of unproven and unlicensed adipose-derived stem cell treatments in US clinics, highlighting concerns about patient safety and regulatory challenges.
2 citations
,
November 2021 in “Regenerative Medicine” This study found that the majority of UK clinics market stem cell treatments ethically questionably, often omitting risk information, exaggerating effectiveness, and using celebrity testimonials.
May 2019 in “Cytotherapy” This study explored how Australian patients and their carers perceived autologous stem cell interventions, highlighting factors like illness experience and unrealistic expectations that influenced their decision-making in an unregulated market.
January 2014 in “Elsevier eBooks” This review discusses the phenomenon of stem cell tourism, highlighting the risks and conflicts parents face when seeking unproven therapies for children's treatments, and reports no new clinical findings.
1 citations
,
May 2019 in “Cytotherapy” This study reviewed changes in marketing practices of Australian clinics after a regulatory ban on direct-to-consumer advertising of stem cell products, finding improvements yet also limitations in addressing misleading claims and consumer safety.
